Biomerica, Inc. (BMRA) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low55.8·High98.7
P/FCF
N/A
—
5yr avg: N/A
30Y Low46.7·High197.4
P/B Ratio
↓
1.24
↓-94% vs avg
5yr avg: 21.43
30Y Low1.7·High64.5
ROE
↓
-93.0%
↑-35% vs avg
5yr avg: -68.9%
30Y Low-93%·High61%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High10.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BMRA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Biomerica, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7M | $7M | $78M | $155M | $355M | $348M | $526M | $166M | $279M | $167M | $98M |
| Enterprise Value | $5M | $5M | $75M | $146M | $350M | $346M | $519M | $165M | $278M | $165M | $96M |
| P/E Ratio → | -1.03 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.23 | 1.32 | 14.41 | 29.06 | 18.80 | 48.39 | 78.62 | 31.89 | 50.15 | 28.76 | 18.99 |
| P/B Ratio | 1.24 | 1.71 | 11.84 | 13.23 | 42.63 | 37.75 | 37.02 | 41.65 | 64.51 | 37.11 | 18.70 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BMRA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.95 | 13.79 | 27.44 | 18.56 | 48.03 | 77.60 | 31.75 | 49.93 | 28.55 | 18.62 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
BMRA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Biomerica, Inc. earns an operating margin of -96.7%. Operating margins have expanded from -135.3% to -96.7% over the past 3 years, signaling improving operational efficiency. A negative ROE of -93.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 9.4% | 9.4% | 11.3% | 8.4% | 15.8% | 5.1% | 26.6% | 24.8% | 31.5% | 34.9% | 29.7% |
| Operating Margin | -96.7% | -96.7% | -117.6% | -135.3% | -24.0% | -104.2% | -35.9% | -46.4% | -26.6% | -16.5% | -16.1% |
| Net Profit Margin | -93.6% | -93.6% | -110.4% | -133.7% | -24.0% | -103.4% | -34.9% | -46.0% | -26.3% | -15.7% | -29.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -93.0% | -93.0% | -65.3% | -71.2% | -51.6% | -63.5% | -25.7% | -57.6% | -33.3% | -18.7% | -27.7% |
| ROA | -65.4% | -65.4% | -50.4% | -55.3% | -39.1% | -51.2% | -20.8% | -45.7% | -28.6% | -16.9% | -25.3% |
| ROIC | -143.5% | -143.5% | -151.8% | -157.6% | -65.2% | -80.3% | -33.9% | -56.4% | -34.8% | -21.7% | -15.8% |
| ROCE | -91.3% | -91.3% | -65.1% | -66.0% | -45.6% | -57.0% | -24.3% | -58.1% | -33.6% | -19.7% | -15.3% |
BMRA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $458000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.12 | 0.09 | 0.17 | 0.18 | 0.13 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.47 | -0.51 | -0.74 | -0.55 | -0.28 | -0.48 | -0.17 | -0.28 | -0.27 | -0.36 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -20435.13 | -266983.11 | -51335.96 | -40047.43 | -3385.22 | -4951.81 |
Net cash position: cash ($2M) exceeds total debt ($458000)
BMRA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Biomerica, Inc.'s current ratio of 2.80x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.95x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 6.58x to 2.80x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.80 | 2.80 | 3.51 | 6.58 | 4.69 | 7.10 | 10.00 | 3.56 | 5.00 | 7.96 | 9.55 |
| Quick Ratio | 1.95 | 1.95 | 2.43 | 5.52 | 3.49 | 4.63 | 8.07 | 1.85 | 2.57 | 4.69 | 5.87 |
| Cash Ratio | 1.38 | 1.38 | 1.89 | 5.00 | 2.94 | 3.23 | 5.85 | 0.54 | 1.34 | 2.32 | 3.73 |
| Asset Turnover | — | 0.89 | 0.59 | 0.37 | 1.66 | 0.61 | 0.39 | 0.99 | 1.07 | 1.15 | 0.90 |
| Inventory Turnover | 3.23 | 3.23 | 2.02 | 2.38 | 6.58 | 2.13 | 1.72 | 1.82 | 1.75 | 2.18 | 1.94 |
| Days Sales Outstanding | — | 50.24 | 63.83 | 49.36 | 14.97 | 73.77 | 96.31 | 102.09 | 52.47 | 66.80 | 68.85 |
BMRA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Biomerica, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $17M | $14M | $13M | $12M | $10M | $9M | $9M | $8M | $8M |
Peer Comparison
Compare BMRA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BMRAYou | $7M | -1.0 | — | — | 9.4% | -96.7% | -93.0% | -143.5% | — |
 CODX | $3M | -0.1 | — | — | 64.3% | -5025.5% | -125.2% | -73.9% | — |
 QDEL | $737M | -0.6 | — | — | 46.7% | -33.7% | -46.1% | -13.6% | — |
 OSUR | $220M | -3.3 | — | — | 41.9% | -59.2% | -18.3% | -20.0% | — |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 BIO | $7B | 9.1 | 16.5 | 18.3 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
 NEOG | $2B | -1.8 | 20.4 | — | 47.1% | 1.1% | -41.9% | 0.2% | 6.8 |
 IDXX | $44B | 42.8 | 30.9 | 42.2 | 61.8% | 31.6% | 66.2% | 42.5% | 0.7 |
 CHEK | $12M | -0.5 | — | — | — | — | -226.2% | -287.7% | — |
 TMO | $173B | 26.2 | 18.7 | 27.5 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $121B | 34.0 | 17.8 | 23.0 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See BMRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BMRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BMRA vs CODX
Side-by-side business, growth, and profitability comparison vs Co-Diagnostics, Inc..
Start ComparisonBMRA — Frequently Asked Questions
Quick answers to the most common questions about buying BMRA stock.
What is Biomerica, Inc.'s P/E ratio?
Biomerica, Inc.'s current P/E ratio is -1.0x. The historical average is 105.0x.
What is Biomerica, Inc.'s ROE?
Biomerica, Inc.'s return on equity (ROE) is -93.0%. The historical average is -17.3%.
Is BMRA stock overvalued?
Based on historical data, Biomerica, Inc. is trading at a P/E of -1.0x. Compare with industry peers and growth rates for a complete picture.
What are Biomerica, Inc.'s profit margins?
Biomerica, Inc. has 9.4% gross margin and -96.7% operating margin.